This is an open-label, dose-escalation phase I study to assess the safety and tolerability of
siCoV/KK46 in healthy volunteers. The purpose of this study is to determine the maximum daily
dose of siCoV/KK46 as a single agent in adult healthy participants. Based on preclinical data
from this institution, the investigators hypothesize that SARS-CoV-2 inhibition with
siCoV/KK46 could potentially reduce pulmonary inflammation, thereby improving COVID-19
patient outcomes.
Phase:
Phase 1
Details
Lead Sponsor:
National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Collaborator:
St. Petersburg Research Institute of Vaccines and Sera